Comparison of clinical efficacy between acitretin and etretinate in psoriasis.
- Author:
Sang Eun MOON
;
Bang Soon KIM
;
Jai Il YOUN
;
Yoo Shin LEE
- Publication Type:Original Article
- Keywords:
Psoriasis;
Acitret.in;
Etretinate
- MeSH:
Acitretin*;
Etretinate*;
Half-Life;
Hand;
Humans;
Incidence;
Psoriasis*
- From:Korean Journal of Dermatology
1992;30(3):354-361
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Etretinate, an effective retinoid in the treatment of pustular, erythrodermic and chronic plaque type psoriasis, has the disadvantage of a long terminal elimination half-life. On the other hand, acitretin, the active metabolite of etretinate, has much shorter terminal elimination half-life and is being reported as an agent with good antipsoriatic activity by several authors. To evaluate the clinical efficacy of acitret.in in comparison with etretinate, we treated 10 patients wit,h acitretin at a dose of 30mg per day and 11 patients with etretinate at a same dose for 12 weeks. The PASI score at 12 week was significantly reduced in each group as compared with baseline PASI score. In the acitretin treated group the initial PASI score of 14.5 reduced to 3.9, while the etretinate group PASI score reduced from 12.0 to 3.1. The PASI score differ ences between the acitretin and etretinate groups at each time during therapy and the end of therapy were not statistically significant. The severity of adverse reactions with acitretin was similar to those with etretinate but their incidence was higher. The change in laboratory parameters in the acitretin group was simlar to that of the etretinate group. In view of these results and the known pharmacokinetic advantage of acitretin, that is the short terminal elimination half-life, it is conceivable that acitretin may be a useful alternative to etretinate in the treatment of psoriasis.
